Boehringer Ingelheim Discontinues Development of BI 1467335 for NASH
Release Date: 18/12/2019 8:36am
Boehringer Ingelheim and Pharmaxis Ltd today announced the discontinuation of the development of BI 1467335 for the treatment of NASH (non-alcoholic steatohepatitis). BI 1467335 was acquired from Pharmaxis in 2015.
In a 12 week Phase IIa trial investigating BI 1467335 in patients with clinical evidence of NASH, treatment was well tolerated and no related serious adverse events occurred. The study met the pre specified targets for inhibition of plasma amine oxidase copper-containing 3 (AOC3) activity by BI 1467335 compared to placebo as well as clinically relevant changes in NASH biomarkers. However, following assessment of another recently completed Phase I study, Boehringer Ingelheim decided not to further develop BI 1467335 in this indication based on the risk of drug interactions of the compound in NASH patients.
Further studies with BI 1467335, including a Phase IIa study in diabetic retinopathy which has completed recruitment and is due to report 2H 2020, remain unaffected by the decision.
Categories: News and Media